Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.21 USD | +1.68% | +12.04% | +52.59% |
Business Summary
Number of employees: 449
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Cell Therapies
100.0
%
| 27 | 100.0 % | 60 | 100.0 % | +122.05% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom
100.0
%
| 27 | 100.0 % | 60 | 100.0 % | +122.05% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 57 | 07-12-31 | |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Gavin Wood
DFI | Director of Finance/CFO | 54 | 20-03-31 |
Joanna Brewer
CTO | Chief Tech/Sci/R&D Officer | 47 | 08-12-31 |
Elliot Norry
CTO | Chief Tech/Sci/R&D Officer | 61 | 15-06-30 |
William Bertrand
COO | Chief Operating Officer | 59 | 17-03-14 |
Juli P. Miller
IRC | Investor Relations Contact | - | 16-07-31 |
Sharp Kerry
LAW | General Counsel | - | 15-09-30 |
Phil Bassett
PRN | Corporate Officer/Principal | - | - |
John Lunger
PRN | Corporate Officer/Principal | 55 | 17-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kristen Hege
BRD | Director/Board Member | 60 | Oct. 31 |
Andrew Allen
BRD | Director/Board Member | 57 | 23-05-31 |
David Mott
CHM | Chairman | 58 | 14-08-31 |
Adrian Rawcliffe
CEO | Chief Executive Officer | 52 | 15-02-28 |
Ali Behbahani
BRD | Director/Board Member | 47 | 14-08-31 |
Garry Menzel
BRD | Director/Board Member | 59 | 23-05-31 |
John Furey
BRD | Director/Board Member | 59 | 18-07-04 |
Lawrence Alleva
BRD | Director/Board Member | 74 | 15-02-28 |
Priti Hegde
BRD | Director/Board Member | 52 | 23-05-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 1,480,950,456 | 223,044,163 ( 15.06 %) | 0 | 15.06 % |
Company contact information
Adaptimmune Therapeutics Plc
60 Jubilee Avenue Milton Park
OX14 4RX, Abingdon
+44 12 3543 0000
http://www.adaptimmune.comSector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.59% | 309M | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+4.40% | 22.25B | |
-14.77% | 21.68B | |
-9.00% | 18.2B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B |
- Stock Market
- Equities
- ADAP Stock
- Company Adaptimmune Therapeutics plc